Obstructive Sleep Apnea (OSA) Pipeline Analysis: Key Companies Advancing the Future of OSA Therapeutics | DelveInsight

DelveInsight's "Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2026" report provides comprehensive global coverage of available, marketed, and pipeline therapies for Obstructive Sleep Apnea (OSA) across different stages of clinical development. Major pharmaceutical and biotechnology companies are actively working to advance the Obstructive Sleep Apnea (OSA) pipeline landscape and improve future treatment outcomes.

Key Takeaways from the Obstructive Sleep Apnea (OSA) Pipeline Report
• DelveInsight's Obstructive Sleep Apnea (OSA) pipeline report depicts a robust pipeline landscape with multiple active companies developing therapies for Obstructive Sleep Apnea (OSA) treatment.
• Key Obstructive Sleep Apnea (OSA) companies such as Apnimed, Incannex Healthcare Inc., Mineralys Therapeutics, Mosanna Therapeutics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and others are evaluating innovative treatment approaches for OSA management.
• Promising Obstructive Sleep Apnea (OSA) pipeline therapies in various stages of development include AD-109, IHL-42X, Lorundrostat, HRS9531, MOS118, and others.

Request a sample and discover the recent advances in Obstructive Sleep Apnea (OSA) treatment therapies. https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Obstructive Sleep Apnea (OSA)?
Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder characterized by repeated obstruction of the upper airway during sleep. The condition occurs when something blocks part or all of the upper airway while the person is asleep, causing shallow breathing or temporary pauses in breathing.

Common symptoms of OSA include loud snoring, daytime sleepiness, fatigue, dry mouth, morning headaches, trouble concentrating, depression, night sweats, and restlessness during sleep. The condition is strongly associated with obesity and is more common in males than females.
Diagnosis of OSA includes polysomnography, Epworth sleepiness scale assessment, and evaluation of respiratory disturbance index (RDI). Treatment focuses on improving nighttime breathing, reducing associated cardiovascular risks, and improving quality of life.

Emerging Obstructive Sleep Apnea (OSA) Drug Profiles

AD-109: Apnimed
AD-109 is an investigational once-daily oral therapy designed to treat obstructive sleep apnea by addressing the neuromuscular cause of upper airway collapse. It combines aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor, to enhance upper airway muscle activity during sleep.
The therapy is currently in Phase III clinical development for the treatment of Obstructive Sleep Apnea (OSA). In the SynAIRgy Phase III trial, AD-109 demonstrated a 55.6% reduction in mean apnea-hypopnea index (AHI) from baseline at 26 weeks. Additionally, 22.3% of participants achieved complete OSA disease control.

IHL-42X: Incannex Healthcare Inc.
IHL-42X is an oral fixed-dose combination therapy being evaluated for the treatment of Obstructive Sleep Apnea (OSA). The therapy is currently in Phase II/III clinical development and has received Fast Track designation from the US Food and Drug Administration (FDA).

Learn more about the novel and emerging Obstructive Sleep Apnea (OSA) pipeline therapies.
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Obstructive Sleep Apnea (OSA) Pipeline Landscape
• In July 2025, Apnimed announced positive topline results from its second pivotal Phase III clinical trial evaluating AD-109 for Obstructive Sleep Apnea (OSA).
• In May 2025, Apnimed announced positive topline results from the first landmark Phase III clinical trial of AD-109, an investigational once-daily oral therapy for OSA.
• In June 2022, Apnimed announced that the US FDA granted Fast Track designation to AD-109 for the treatment of Obstructive Sleep Apnea (OSA).
• In December 2025, Incannex Healthcare Inc. announced that the US FDA granted Fast Track designation for IHL-42X for the treatment of obstructive sleep apnea.
• In September 2025, Mineralys Therapeutics announced completion of enrollment in its Phase II EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe OSA and hypertension.
• In June 2025, Mosanna Therapeutics announced the close of USD 80 million in Series A funding to support development of its nighttime nasal spray therapy for Obstructive Sleep Apnea (OSA).

Scope of the Obstructive Sleep Apnea (OSA) Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Preclinical, Phase I, Phase II, Phase II/III, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Subcutaneous, Intranasal, Parenteral
• Therapeutics Assessment By Molecule Type: Small molecule, Peptide, Monoclonal antibody, Polymer, Gene Therapy
• Key Obstructive Sleep Apnea (OSA) Companies: Apnimed, Incannex Healthcare Inc., Mineralys Therapeutics, Mosanna Therapeutics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and others
• Key Obstructive Sleep Apnea (OSA) Pipeline Therapies: AD-109, IHL-42X, Lorundrostat, HRS9531, MOS118, and others

Dive deep into rich insights for emerging Obstructive Sleep Apnea (OSA) therapies and treatment trends.
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
• Obstructive Sleep Apnea (OSA) Pipeline Report Introduction
• Obstructive Sleep Apnea (OSA) Pipeline Executive Summary
• Obstructive Sleep Apnea (OSA): Overview
• Analytical Perspective In-depth Commercial Assessment
• Obstructive Sleep Apnea (OSA) Pipeline Therapeutics
• Late Stage Products (Phase III)
• Mid Stage Products (Phase II)
• Early Stage Products (Phase I/II)
• Early Stage Products (Phase I)
• Preclinical and Discovery Stage Products
• Therapeutic Assessment
• Inactive Products Analysis
• Collaborations Assessment- Licensing / Partnering / Funding
• Key Companies
• Key Products in the Obstructive Sleep Apnea (OSA) Pipeline
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives and Conclusion
• Analyst Views
• Appendix

For further information on the Obstructive Sleep Apnea (OSA) pipeline therapeutics, reach out to DelveInsight.
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.